Deciphera Pharmaceuticals logo
Deciphera Pharmaceuticals DCPH

Annual report 2023
added 02-07-2024

report update icon

Deciphera Pharmaceuticals Gross Profit 2011-2025 | DCPH

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Quarterly Gross Profit Deciphera Pharmaceuticals

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - - - - - - 19.4 M 15.4 M 7.08 M 62 K - - 25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
25 M 62 K 13.4 M

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-40.6 M $ 4.79 2.57 % $ 795 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
172 K $ 3.39 1.02 % $ 262 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-32.3 K - 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
1.12 M - -15.15 % $ 60.3 M britainBritain
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-523 K - -11.43 % $ 502 K usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
319 M $ 213.61 1.64 % $ 5 B danmarkDanmark
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
39.2 M - -0.23 % $ 916 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
90 K - - $ 7.46 M israelIsrael
Aptorum Group Limited Aptorum Group Limited
APM
-104 K $ 1.32 -0.75 % $ 7.2 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
177 K $ 3.39 -0.88 % $ 8.16 B australiaAustralia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
43.9 B $ 89.7 -0.64 % $ 96.9 B britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
374 M $ 25.67 -0.87 % $ 1.24 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
103 M $ 9.55 0.63 % $ 140 M usaUSA
Brickell Biotech Brickell Biotech
BBI
1.82 K - -5.38 % $ 6.06 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
3.22 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
500 - -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
53.8 M - -7.31 % $ 87 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
45.8 M $ 2.33 2.19 % $ 14.6 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
319 K - -6.81 % $ 3.04 B usaUSA
Baudax Bio Baudax Bio
BXRX
-1.24 M - 0.59 % $ 63 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
ChromaDex Corporation ChromaDex Corporation
CDXC
61.6 M - -0.88 % $ 598 M usaUSA
Axon Enterprise Axon Enterprise
AXON
1.24 B $ 573.02 -1.38 % $ 43.4 B usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
1.07 - - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
4.15 M - -16.75 % $ 25.8 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
123 M - -7.23 % $ 13 M usaUSA
Biogen Biogen
BIIB
12.4 B $ 174.8 1.33 % $ 25.5 B usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
371 M $ 11.54 0.87 % $ 746 M usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
282 K $ 12.57 -3.01 % $ 517 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
200 K - -5.68 % $ 8.28 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.27 M - 2.71 % $ 14 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
2.03 M $ 0.29 -1.45 % $ 631 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
109 M $ 15.4 0.59 % $ 1.01 B usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
37.5 K - - $ 40.5 M usaUSA
Epizyme Epizyme
EPZM
10.7 M - - $ 249 M usaUSA
Cerus Corporation Cerus Corporation
CERS
60.4 M $ 2.22 3.02 % $ 410 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA